Advances in adoptive cell therapies in small cell lung cancer DOI Creative Commons

Eljie Isaak Bragasin,

Justin Cheng, Lauren Ford

и другие.

Exploration of Targeted Anti-tumor Therapy, Год журнала: 2025, Номер 6

Опубликована: Март 26, 2025

Small cell lung cancer (SCLC) is an aggressive tumor characterized by early metastasis and resistance to treatment, making it a prime target for therapeutic investigation. The current standard of care frontline treatment involves combination chemotherapeutic agents immune checkpoint inhibitors (ICIs), though durability response remains limited. genetic heterogeneity SCLC also complicates the development new options. Adoptive therapies show promise targeting specific mutations in order increase efficacy minimize toxicity. There has been significant investigation three classes application towards SCLC: antibody drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), chimeric antigen receptor (CAR)-T therapies. This review summarizes recent advances challenges adoptive Genetic targets such as delta-like ligand 3 (DLL3), trophoblast surface 2 (Trop2), B7-H3 (CD276), gangliosides disialoganglioside GD2 (GD2) ganglioside GM2 (GM2) have found be expressed SCLC, which makes them therapy development. While investigated rovalpituzumab tesirine (Rova-T) failed, several insights from these trials led compelling sacituzumab govitecan (SG), ifinatamab deruxtecan (I-DXd), tarlatamab, DLL3-targeted CAR-T cells. Advancing molecular testing improving targeted approaches remain integral pushing forward progress SCLC.

Язык: Английский

Advances in adoptive cell therapies in small cell lung cancer DOI Creative Commons

Eljie Isaak Bragasin,

Justin Cheng, Lauren Ford

и другие.

Exploration of Targeted Anti-tumor Therapy, Год журнала: 2025, Номер 6

Опубликована: Март 26, 2025

Small cell lung cancer (SCLC) is an aggressive tumor characterized by early metastasis and resistance to treatment, making it a prime target for therapeutic investigation. The current standard of care frontline treatment involves combination chemotherapeutic agents immune checkpoint inhibitors (ICIs), though durability response remains limited. genetic heterogeneity SCLC also complicates the development new options. Adoptive therapies show promise targeting specific mutations in order increase efficacy minimize toxicity. There has been significant investigation three classes application towards SCLC: antibody drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), chimeric antigen receptor (CAR)-T therapies. This review summarizes recent advances challenges adoptive Genetic targets such as delta-like ligand 3 (DLL3), trophoblast surface 2 (Trop2), B7-H3 (CD276), gangliosides disialoganglioside GD2 (GD2) ganglioside GM2 (GM2) have found be expressed SCLC, which makes them therapy development. While investigated rovalpituzumab tesirine (Rova-T) failed, several insights from these trials led compelling sacituzumab govitecan (SG), ifinatamab deruxtecan (I-DXd), tarlatamab, DLL3-targeted CAR-T cells. Advancing molecular testing improving targeted approaches remain integral pushing forward progress SCLC.

Язык: Английский

Процитировано

0